Search Results - "Gettinger, S"

Lichenoid drug eruption induced by letrozole: a case report.

Authors: Alhusaini, Yara M Almufadhi, Abdulaziz A Sayed, Ayah K et al.

Source: Oxford Medical Case Reports. Jun2026, Vol. 2026 Issue 6, p1-3. 3p.

AUTHOR INDEX.

Source: Asia Pacific Journal of Clinical Oncology. Nov2017 Supplement S5, Vol. 13, p225-235. 11p.

A radio-pathological fusion model for predicting PD-L1 expression and immunotherapy response in non-small cell lung cancer.

Authors: Huang, Dingpin Xu, Fangyi Gan, Yi et al.

Source: Insights into Imaging. 6/15/2026, Vol. 17 Issue 1, p1-14. 14p.

Panax notoginseng Saponins Enhance Chemotherapy Carboplatin and Immune Checkpoint Blockades PD1ab by Modulating SERPINE1 Downregulation in LUAD.

Authors: Wang, Yuhuai Wang, Ping Liu, Jiaqi et al.

Source: Pharmacognosy Magazine. Jun2026, Vol. 22 Issue 2, p605-615. 11p.

Immune Checkpoint Inhibitor-Associated Diabetes Mellitus: Future Perspectives and Emerging Therapies.

Authors: Karavendzas, Jean-Luc Galligan, Anna Lee, Melissa H. et al.

Source: Endocrines. Jun2026, Vol. 7 Issue 2, p18. 14p.

Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR -Mutant Non-Small Cell Lung Cancer: A Case Series.

Authors: Liu, Po-Tsen Chen, Yi-Lin Chen, Wan-Li et al.

Source: Current Oncology. Jun2026, Vol. 33 Issue 6, p311. 12p.

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

Authors: Richani Meinhardt, Fedor Wadi Zambrano Iglesias, Mijail I. Fernández Gómez, María P. et al.

Source: International Journal of Molecular Sciences. Jun2026, Vol. 27 Issue 11, p4910. 15p.

Prognostic Value of 18 F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab.

Authors: Kocaaslan, Erkam Güren, Ali Kaan Akagündüz, Fırat et al.

Source: Journal of Clinical Medicine. Jan2026, Vol. 15 Issue 2, p798. 13p.

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Authors: Watanabe, Makoto Ieguchi, Katsuaki Shimizu, Takashi et al.

Source: Cancers. Jul2025, Vol. 17 Issue 14, p2384. 14p.

Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.

Authors: Cortellini A Garbo E La Cava G et al.

Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2025 Nov; Vol. 209, pp. 108799. Date of Electronic Publication: 2025 Oct 16.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter Study.

Authors: Merc Cetinkaya, Aysegul Yucel, Mehmet Haluk Karahan, Latif et al.

Source: Journal of Clinical Medicine. Apr2026, Vol. 15 Issue 8, p2818. 12p.

Short versus long corticosteroid therapy for immune checkpoint inhibitors–induced acute tubulointerstitial nephritis.

Authors: Auñón, Pilar Lopes, Vanessa Minguez, Irene et al.

Source: Clinical Kidney Journal. Apr2026, Vol. 19 Issue 4, p1-11. 11p.

Cutaneous Skin Toxicities of Oncological Targeted Therapies: Comprehensive Overview of Mechanisms, Management, and Research Gaps—A Narrative Review.

Authors: Janicki, Piotr Makowska, Anna Jakubczyk-Słabicka, Anna et al.

Source: Dermatology & Therapy. Apr2026, Vol. 16 Issue 4, p1847-1868. 22p.

Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis.

Authors: Çelik, Selahattin Kavak, Engin Eren Zeynelgil, Esra et al.

Source: Journal of Clinical Medicine. Apr2026, Vol. 15 Issue 7, p2475. 14p.

PD-L1 Negative Advanced Non-Small Cell Lung Cancer: Practice Patterns and Real-World Outcomes.

Authors: Bégin, Audrey-Ann Dubé-Pelletier, Maude Labbé, Catherine et al.

Source: Current Oncology. Mar2026, Vol. 31 Issue 3, p144. 13p.

Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers.

Authors: Miura, Yu Imai, Hisao Endo, Satoshi et al.

Source: Current Oncology. Mar2026, Vol. 31 Issue 3, p135. 19p.

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.

Authors: Wang, Yuanyuan Guo, Haoyue Han, Ruoshuang et al.

Source: Cellular Oncology (2211-3428). Feb2026, Vol. 49 Issue 1, p1-13. 13p.

Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression.

Authors: Blomquist, Mylan R. Noviello, Teresa M. R. Sereduk, Christopher et al.

Source: Journal of Translational Medicine. 10/21/2025, Vol. 23 Issue 1, p1-16. 16p.

Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition.

Authors: Rock, Adam Mambetsariev, Isa Pareek, Siddhika et al.

Source: Current Oncology. Oct2025, Vol. 32 Issue 10, p554. 11p.

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.

Authors: Mason, Mike Lapuente-Santana, Óscar Halkola, Anni S. et al.

Source: Journal of Translational Medicine. 4/21/2024, Vol. 22 Issue 1, p1-16. 16p.